Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Other Working Capital Changes: 2014-2025

Historic Other Working Capital Changes for KalVista Pharmaceuticals (KALV) over the last 8 years, with Apr 2025 value amounting to $10.5 million.

  • KalVista Pharmaceuticals' Other Working Capital Changes rose 625.83% to $10.5 million in Q2 2025 from the same period last year, while for Apr 2025 it was $10.6 million, marking a year-over-year increase of 1871.00%. This contributed to the annual value of $10.6 million for FY2025, which is 1862.45% up from last year.
  • According to the latest figures from Q2 2025, KalVista Pharmaceuticals' Other Working Capital Changes is $10.5 million, which was up 598.15% from -$2.1 million recorded in Q4 2024.
  • In the past 5 years, KalVista Pharmaceuticals' Other Working Capital Changes registered a high of $10.5 million during Q2 2025, and its lowest value of -$2.1 million during Q4 2024.
  • Moreover, its 3-year median value for Other Working Capital Changes was $783,000 (2024), whereas its average is $1.4 million.
  • As far as peak fluctuations go, KalVista Pharmaceuticals' Other Working Capital Changes decreased by 21.93% in 2024, and later skyrocketed by 625.83% in 2025.
  • Over the past 3 years, KalVista Pharmaceuticals' Other Working Capital Changes (Quarterly) stood at -$1.8 million in 2023, then decreased by 19.27% to -$2.1 million in 2024, then skyrocketed by 625.83% to $10.5 million in 2025.
  • Its Other Working Capital Changes was $10.5 million in Q2 2025, compared to -$2.1 million in Q4 2024 and $783,000 in Q3 2024.